News
Mathieu Roche discusses the role of identity in digital advertising performance, emphasizing transparent data collection and ...
Roche discontinued the commercial and clinical use of Elevidys after two cases of fatal acute liver failure. The Swiss ...
10h
Stocktwits on MSNMAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock SoarsShares of MAIA Biotechnology, Inc. (MAIA) soared 12% on Wednesday morning after the company said that it entered into a ...
Former club captain Barry Roche leaves Morecambe after 17 years at the Shrimps that spanned both playing and coaching roles.
The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...
Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...
Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...
Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...
Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...
2d
GlobalData on MSNSarepta and Roche halt DMD gene therapy’s use after second deathShares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.
With fewer than 200 trained dermatologists serving Malaysia's 33 million people[1]-just one specialist for every 165,000 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results